Amna Ibrahim

6.7k citations

64 papers · 5.3k · 2 hit papers · h-index 38

Impact in

Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Pulmonary and Respiratory Medicine top 2%
- Advanced Breast Cancer Therapies
- Prostate Cancer Treatment and Research

Papers in

Pulmonary and Respiratory Medicine 28
- Advanced Breast Cancer Therapies 10
- Prostate Cancer Treatment and Research 8
- Renal cell carcinoma treatment 7
Oncology 24
- HER2/EGFR in Cancer Research 10
- Cancer Treatment and Pharmacology 7

Co-authors: Richard M. Pazdur (31 shared papers)Rajeshwari Sridhara (21 shared papers)Shenghui W. Tang (23 shared papers)Robert L. Justice (8 shared papers)Julia A. Beaver (16 shared papers)Martin H. Cohen (4 shared papers)Kirsten B. Goldberg (11 shared papers)Laleh Amiri‐Kordestani (11 shared papers)
Journals: Clinical Cancer Research (26 papers)The Oncologist (9 papers)Journal of Clinical Oncology (3 papers)JAMA Oncology (2 papers)Annals of Oncology (2 papers)
Partner nations: United States Egypt Jordan

In The Last Decade

Amna Ibrahim

62 papers receiving 5.2k citations

Amna Ibrahim's Hit Papers

align trajectories log scale

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer 2022 · 166 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2022 Clinical Cancer Research
2015 Clinical Cancer Research

Peers

Countries citing papers authored by Amna Ibrahim

Since Specialization

Citations

This map shows the geographic impact of Amna Ibrahim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amna Ibrahim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amna Ibrahim more than expected).

Fields of papers citing papers by Amna Ibrahim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amna Ibrahim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amna Ibrahim. The network helps show where Amna Ibrahim may publish in the future.

Co-authors

The 25 scholars most cited alongside Amna Ibrahim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amna Ibrahim Line = papers co-authored together Amna Ibrahim links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 64 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy Clinical Cancer Research ·Geoffrey Kim, Gwynn Ison, Amy E. McKee, Hui Zhang, Shenghui W. Tang, Thomas E. Gwise, Rajeshwari Sridhara, Eunice Lee Hit paper breakdown →	2015	456
2	FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer Clinical Cancer Research ·Julia A. Beaver, Laleh Amiri‐Kordestani, Rosane Charlab, Wei Chen, Todd R. Palmby, Amy Tilley, Jeanne Fourie Zirkelbach, Jingyu Yu	2015	302
3	FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer Clinical Cancer Research ·Laleh Amiri‐Kordestani, Gideon Michael Blumenthal, Qiang Xu, Lijun Zhang, Shenghui W. Tang, Linan Ha, Wendy C. Weinberg, Bo Chi	2014	300
4	Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody Journal of Clinical Oncology ·Virginia Ellen Maher, Laura L. Fernandes, Chana Weinstock, Shenghui W. Tang, Sundeep Agarwal, Michael Holman Brave, Yangmin M. Ning, Harpreet Singh	2019	268
5	FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2 The Oncologist ·Qin C. Ryan, Amna Ibrahim, Martin H. Cohen, John R. Johnson, Chia‐Wen Ko, Rajeshwari Sridhara, Robert L. Justice, Richard M. Pazdur	2008	259
6	CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis The Lancet Oncology ·Jennifer J. Gao, Joyce Cheng, Erik W. Bloomquist, Jacquelyn Sanchez, Suparna Bonthala Wedam, Harpreet Singh, Laleh Amiri‐Kordestani, Amna Ibrahim	2019	235
7	FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma The Oncologist ·Virginia E. Kwitkowski, Tatiana Michelle Prowell, Amna Ibrahim, Ann T. Farrell, Robert L. Justice, Shan Sun Mitchell, Rajeshwari Sridhara, Richard M. Pazdur	2010	220
8	FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation Clinical Cancer Research ·Geoffrey Kim, Amy E. McKee, Yangmin M. Ning, Maitreyee Hazarika, Marc Robert Theoret, John R. Johnson, Qiang Casey Xu, Shenghui Tang	2014	177
9	Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. PubMed ·Amna Ibrahim, Nancy S. Scher, Grant Williams, Rajeshwari Sridhara, Ning Li, Gang Chen, John Charles Leighton, Brian P. Booth	2003	167
10	FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer Clinical Cancer Research ·Jaleh Fallah, Sundeep Agrawal, Haley R Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy S. John, Wei Chen, Tiffany K. Ricks Hit paper breakdown →	2022	166
11	FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma Clinical Cancer Research ·Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao U. T. Gong, Vicky Hsu, Fang Li	2020	156
12	FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy The Oncologist ·Daniel L. Suzman, Sundeep Agrawal, Yangmin M. Ning, Virginia Ellen Maher, Laura L. Fernandes, Stella Wanjugu Karuri, Shenghui W. Tang, Rajeshwari Sridhara	2018	155
13	FDA Drug Approval Summaries: Oxaliplatin The Oncologist ·Amna Ibrahim, Steven Hirschfeld, Martin H. Cohen, Donna J. Griebel, Grant A. Williams, Richard M. Pazdur	2004	150
14	Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary Clinical Cancer Research ·Paul Gustav Kluetz, William F. Pierce, Virginia Ellen Maher, Hui Zhang, Shenghui W. Tang, Pengfei Song, Qi Liu, Martin T. Haber	2013	142
15	Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary Clinical Cancer Research ·Katherine Anne Thornton, Geoffrey Kim, Virginia Ellen Maher, Somesh Chattopadhyay, Shenghui W. Tang, Young Jin Moon, Pengfei Song, Anshu Marathe	2012	131
16	FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1 Clinical Cancer Research ·Preeti Narayan, Sakar Wahby, Jennifer J. Gao, Laleh Amiri‐Kordestani, Amna Ibrahim, Erik W. Bloomquist, Shenghui W. Tang, Yuan Xu	2020	131
17	FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors Clinical Cancer Research ·Jaleh Fallah, Michael Holman Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford, Haley R Gittleman, Erik W. Bloomquist, Rosane Charlab	2022	125
18	First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer Clinical Cancer Research ·Laleh Amiri‐Kordestani, Suparna Bonthala Wedam, Lijun Zhang, Shenghui W. Tang, Amy Tilley, Amna Ibrahim, Robert L. Justice, Richard M. Pazdur	2014	125
19	External control arms in oncology: current use and future directions Annals of Oncology ·Pallavi Shruti Mishra-Kalyani, L. Amiri Kordestani, Donna R. R Rivera, Harpreet Singh, Amna Ibrahim, R. Angelo DeClaro, Yuan Li Shen, Shenghui W. Tang	2022	105
20	FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy Clinical Cancer Research ·Gwynn Ison, Lynn Jackson Howie, Laleh Amiri‐Kordestani, Lijun Zhang, Shenghui W. Tang, Rajeshwari Sridhara, Vadryn Pierre, Rosane Charlab	2018	103

About Amna Ibrahim

Amna Ibrahim is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Reproductive Medicine, having authored 64 papers that have together received 5.3k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (10 papers), Advanced Breast Cancer Therapies (10 papers), Prostate Cancer Treatment and Research (8 papers), Radiopharmaceutical Chemistry and Applications (7 papers), Cancer Treatment and Pharmacology (7 papers), Renal cell carcinoma treatment (7 papers), Breast Cancer Treatment Studies (6 papers) and Cancer Genomics and Diagnostics (5 papers). The work is most often cited by research in Oncology (2.7k citations), Pulmonary and Respiratory Medicine (1.5k citations), Cancer Research (617 citations), Radiology, Nuclear Medicine and Imaging (701 citations) and Genetics (263 citations). Amna Ibrahim has collaborated with scholars based in United States, Egypt and Jordan. Frequent co-authors include Richard M. Pazdur, Rajeshwari Sridhara, Shenghui W. Tang, Robert L. Justice, Julia A. Beaver, Martin H. Cohen, Kirsten B. Goldberg, Laleh Amiri‐Kordestani, Paul Gustav Kluetz and Virginia Ellen Maher. Their work appears in journals such as Clinical Cancer Research, The Oncologist, Journal of Clinical Oncology, JAMA Oncology and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Amna Ibrahim

Impact in

Papers in i

In The Last Decade

Amna Ibrahim

Amna Ibrahim's Hit Papers

Peers

Countries citing papers authored by Amna Ibrahim

Fields of papers citing papers by Amna Ibrahim

All Works

About Amna Ibrahim

Explore authors with similar magnitude of impact

Papers in